What we do Dipna Pharmachem Limited trades, imports, and exports pharmaceutical raw materials, APIs, and chemicals with a diversified product portfolio serving pan-India and global clients. |
Founded in 2,011 |
Market share Recognized for quality and innovation in pharmaceutical raw materials, with growing pan-India distribution since 2011. |
Problem solved Facilitates access to diverse APIs and chemical raw materials crucial for pharmaceutical formulations, ensuring supply chain efficiency and innovation. |
Top clients or who we serve Pharmaceutical and chemical manufacturers across India and globally; operates in B2B import-export and distribution markets. |
Key management - |
Our journey and innovations Incorporated in 2011, converted to public limited in 2022, expanded chemical trading in 2022, raised Rs 15.2 Cr via IPO. |
Where we operate Pan-India market with import-export services worldwide, headquartered in Ahmedabad, Gujarat. |
Top products or what we offer Over 61 APIs and intermediates covering Cephalosporins, Cardiovasculars, Anti-bacterial, Quinolones, and other therapeutic segments. |
Top brands - |
Raw materials needed APIs and pharmaceutical raw materials sourced globally. |
Raw materials supplier Suppliers worldwide for APIs and chemical raw materials. |
Recurring vs cyclical contribution Revenue primarily from recurring B2B supply contracts with seasonal variations. |
Our industry position Emerging competitive player with strong pan-India reach and innovative services in pharmaceutical raw material trade. |
Financial highlights FY 2024-25 Revenue Rs 124.92 Cr; Net Profit Rs 0.97 Cr; Stable profitability with active growth efforts. |
Geographical revenue split Majority revenue from Indian market with international import-export operations. |
Order book - |
Whats driving growth Expansion into chemical trading, IPO funding, and broadening API portfolio supports growth. |
Our future plans Exploring new business avenues and continuous portfolio expansion to drive future growth. |
Our green promise - |
Our people and values Committed to ethical business conduct, transparency, and supportive work culture. |
Key challenges ahead Market competition and supply chain management remain challenges amid growth aspirations. |
Interesting facts Successfully transitioned from private to public limited company and raised IPO capital in 2022. |
Risks and strategy Focus on maintaining regulatory compliance, enhancing internal controls, and diversifying supplier base. |
